Cargando…
Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017)
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578365/ https://www.ncbi.nlm.nih.gov/pubmed/37908263 http://dx.doi.org/10.1210/jcemcr/luad005 |
| _version_ | 1785121503915802624 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10578365 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105783652023-10-31 Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017) JCEM Case Rep Correction Oxford University Press 2023-01-24 /pmc/articles/PMC10578365/ /pubmed/37908263 http://dx.doi.org/10.1210/jcemcr/luad005 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Correction Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017) |
| title | Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017) |
| title_full | Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017) |
| title_fullStr | Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017) |
| title_full_unstemmed | Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017) |
| title_short | Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017) |
| title_sort | correction to “glucagon-like peptide-1 receptor agonist treatment with semaglutide in type 1 diabetes” (j clin endo metab case reports. 2023; 1(1): 10.1210/jcemcr/luac017) |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578365/ https://www.ncbi.nlm.nih.gov/pubmed/37908263 http://dx.doi.org/10.1210/jcemcr/luad005 |